Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
40.59
-7.91 (-16.31%)
At close: Jan 10, 2025, 4:00 PM
40.99
+0.40 (0.99%)
After-hours: Jan 10, 2025, 4:37 PM EST
Crinetics Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for CRNX stock have an average target of 74.4, with a low estimate of 54 and a high estimate of 97. The average target predicts an increase of 83.30% from the current stock price of 40.59.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CRNX stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 9 | 9 | 8 | 8 | 7 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 11 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $87 | Buy | Reiterates | $87 | +114.34% | Dec 16, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $70 → $74 | Strong Buy | Maintains | $70 → $74 | +82.31% | Nov 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $69 → $81 | Strong Buy | Maintains | $69 → $81 | +99.56% | Nov 13, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $80 | Buy | Reiterates | $80 | +97.09% | Sep 27, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $90 | Buy | Reiterates | $90 | +121.73% | Sep 16, 2024 |
Financial Forecast
Revenue This Year
1.65M
from 4.01M
Decreased by -58.93%
Revenue Next Year
4.87M
from 1.65M
Increased by 195.21%
EPS This Year
-3.78
from -3.69
EPS Next Year
-3.96
from -3.78
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 6.3M | 7.4M | 59.9M | |||
| Avg | 1.6M | 4.9M | 37.1M | |||
| Low | 980,000 | 2.9M | 26.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 57.0% | 346.0% | 1,130.2% | |||
| Avg | -58.9% | 195.2% | 662.0% | |||
| Low | -75.6% | 78.4% | 449.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.68 | -2.57 | -3.81 | |||
| Avg | -3.78 | -3.96 | -4.63 | |||
| Low | -3.90 | -5.29 | -5.92 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.